Abzu reveals insights in Peptomyc’s first-ever clinically viable Myc oncogene inhibitor
The QLattice® discovery engine developed by Abzu® has accelerated scientific exploration and understanding or Peptomyc®, a biotech focused on inhibiting the cancer-causing protein Myc.
Abzu awarded multi million EIC Accelerator grant
Abzu is one of 75 selected in the highly competitive June cutoff of the 2022 EIC Accelerator program.
Abzu® is named a 2022 Gartner® “Cool Vendor”
The Abzoids are proud to share that Abzu is named a “Cool Vendor” in the 2022 Gartner Cool Vendors in AI Governance and Responsible AI — From Principles to Practice report, an annual evaluation of commercial platforms for data science and machine learning (ML), as well as for cloud AI services platforms. These platforms use […]
Abzu appoints Mette Kirstine Agger as a member of the board
Abzu, an artificial intelligence deeptech startup, is elevating its position in the life sciences with a heavy profile in biotech, Mette Kirstine Agger, appointing her as a new member of their board. For the past 12 years, Mette Kirstine Agger has been part of the management team at Lundbeckfonden and Managing Partner for Lundbeckfonden Ventures, […]
Abzu announces a new location at the Switzerland Innovation Park Basel Area – Novartis Campus
Believing in the European vision for AI This marks Abzu’s third office in Europe and the first expansion of its physical footprint since Abzu’s inception in January 2018 with joint offices in Copenhagen, Denmark and Barcelona, Spain. “Our goal is to become the leading European AI company,” says co-founder Casper Wilstrup. “Our story is that […]
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases using xAI technology
According to recent research in European Journal of Human Genetics, there are more than 6.000 rare diseases affecting more than 300 million people world-wide. Today, only 450 FDA-approved orphan drug products are available, which leaves hundreds of millions suffering from chronic diseases and at risk of early death. Nucleic acid-based medicine (NABM), also known as RNA therapeutics, is […]
Record-breaking investment in groundbreaking Danish AI: Abzu announces a 5.8m € seed round
Introducing: A new standard of interpretability in AI Abzu’s pioneering technology, the QLattice®, introduces a new standard of interpretability to artificial intelligence, a domain that has lacked the crucial elements of transparency and explainability required to realize its full potential – until now. “Incumbent AI platforms still struggle with interpretability,” says Casper Wilstrup, CEO of […]
Abzu selected to join the Endless Frontier Labs 2020 – 2021 cohort
Jonas Wilstrup, Operations and Finance at Abzu, says, “It is an exciting step for Abzu that the NYU Stern School of Business has chosen us to be part of the Endless Frontier Labs program. We are truly breaking the mold with our unique and game-changing approach to AI, and we are over the moon that […]
Two Danish startups fight false news using artificial intelligence
The Reuters Institute for the Study of Journalism reported in January 2020 that less than four in ten people trust most news most of the time. Only 38% of more than 80,000 people surveyed in 40 countries trusted most news, a fall of four percentage points from 2019[1]. False news is an increasing global “infodemic”. […]
Abzu receives 1MM DKK grant for innovative, explainable artificial intelligence
Innovation Fund Denmark, which supports innovative ideas, established Innobooster People as a COVID-19 response grant to fund promising knowledge-based Danish start-ups. Funded companies must demonstrate a novel and innovative solution, business potential, a clear implementation plan and skilled team, and financial efficiency. Based dually in Copenhagen and Barcelona, Abzu’s proprietary technology is solving for the […]